Abstract: Disclosed herein is a core-shell microcapsule slurry including at least one core-shell microcapsule. The at least one core-shell microcapsule includes an oil-based core including a hydrophobic material, a polymeric shell and a coating having a functionalized chitosan derivative. Further disclosed herein are the core-shell microcapsule as well as methods for preparing the same and applications thereof.

Abstract: This invention relates to a liquid product in the form of an oil in water or a water in oil emulsion stabilized by a cyclodextrin, methods for obtaining the emulsions, consumer products, and uses thereof.

Abstract: Disclosed is a leave-on water-in-oil cosmetic emulsion that includes an aqueous phase comprising water and a hydrophilic thickening agent consisting of polyvinylpyrrolidone, the aqueous phase being free of other hydrophilic thickening agents, a mattifying filler including a silicone elastomer, an organic ultraviolet filter consisting of octyl salicylate, at least one silicone oil, and at least one silicone emulsifier.

Abstract: The present invention provides a concealer sunscreen cream and its preparation method; including the following weight percentages of each component: polydimethylsiloxane PEG-10/15 cross-linked polymer/polydimethylsiloxane 3%, KF6038 1.5%, polyglyceryl-3 diisostearate 0.3%, KSP-300 1.0%, KSP-100 1.5%, bismuth chloride 1.8%, coconut oil-caprylic/capric acid esters 2%, ethylhexyl hydroxy stearate 2%, KP-545 2%, isonononyl isononanoate 2%, silicone oil 1.5%, Ve 0.5%, synthetic wax SW3254 2%, synthetic wax M80 4%, D5 10%, low viscosity silicone oil 1%, silicone bullet 4%, glycerin 5%, butylene glycol 4%, glycerin polyether-26 5%, magnesium sulfate 0.7%, Pro-Xylane 5%, water 39.15%, aluminum octyl succinate 0.5%, phenoxyethanol 0.3%, chlorphenesin 0.15%, fragrance 0.1%.

Abstract: A solid avocado oil is characterized in that its palmitic acid content in relation to total fatty acids is between 15 and 35% and its complete melting point is within a range of from 20 to 50° C., the avocado oil being obtained from avocado of a variety selected from the list consisting of Hass, Fuerte, Bacon, Pinkerton, Ettinger, Lula, Ryan, Barker, and/or Peruano. A cosmetic or pharmaceutical composition is characterized in that it comprises, in a cosmetically or pharmaceutically acceptable vehicle, a solid avocado oil according to the invention. A method for obtaining a solid avocado oil is characterized in that it is carried out on fresh or dehydrated fruit, crude avocado oils, or co-products from the refining or dewaxing of crude avocado oils.

Abstract: Oral care compositions with an anticaries or anticavity effect. Oral care compositions that have one or more hops beta acids, such as from an extract from a species in the Humulus family, and one or more amino acids. Oral care compositions having one or more amino acids and an extract from Humulus lupulus. Methods of use of the disclosed compositions to disrupt biofilm in the oral cavity of a patient in need of treatment.

Abstract: The present invention relates to the cosmetic use of a lipophilic Solanum lycopersicum fruit peel extract comprising at least 5% by weight of amyrins, at least 1.5% by weight of sterols, and at most 0.5% by weight of lycopene for maintaining, restoring and/or balancing, or reinforcing the natural defenses of the skin or mucous membranes.

Abstract: The present disclosure relates to a composition for skin whitening containing a Nypa fruticans extract as an active ingredient. The composition has an effect of reducing melanin content and inhibiting melanogenesis, and enhances a skin whitening effect by enhancing autophagy activity, and thus can be used in a cosmetic composition, a health functional food composition, and a pharmaceutical composition.

Abstract: Described herein are methods of improving the appearance of skin, or at least one sign of skin aging, using Micrococcus luteus compositions. The invention also relates to topical compositions, kits useful in such methods, and to methods of manufacturing topical compositions.

Abstract: Release of a neurological drug in a targeted region of a subject's brain by a drug delivery system (DDS) is intentionally caused by the subject watching or interacting with an audio/video-based task on an electronic display. The DDS is calibrated to release the neurological drug based on a particular pH, lactate level, blood flow, temperature, magnetic field, specific molecules released by brain cells, or other physiological factors within the target region. The interactive task produces the physiological factors in the brain in specific areas of pathology for which the drug is prescribed, and limits drug delivery at areas unaffected by illness where it could disrupt normal function, causing problematic side effects and preventing dose levels optimal for target impact. Feedback from the interactive task and associated cognitive probes also can adapt the interactive task or suggest new pharmacologic agents as the degree or primary focus of brain pathology changes during the course of treatment.

Abstract: Formulations comprising one or more active agents for blood storage and transfusions are provided. Also provided methods for prolonging viability of blood and enhancing efficacy of blood transfusion.

Abstract: The present invention relates to a self-assembled nanoparticle releasing microneedle structure which is formed of biocompatible amphiphilic block copolymers containing a drug, and a preparation method therefor. The microneedle structure according to the present invention can deliver a water-soluble or hydrophobic drug while being carried in a microneedle. In particular, since a fat-soluble drug is delivered while being carried by micelle-type self-assembled nanoparticles which are formed as the structure is dissolved, it is possible to greatly increase the solubility in an aqueous solution. As such, existing drugs with poor absorption can be delivered through the skin of a body.

Abstract: The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

Abstract: The present invention provides a depot composition suitable to deliver a VMAT2 inhibitor in a controlled manner. The composition of the present invention comprises: (a) a VMAT2 inhibitor and (b) a pharmaceutically acceptable oil. Optionally, the depot composition of the present invention also comprises an excipient to achieve optimal delivery of the VMAT2 inhibitor. The present invention also provides a method for making such depot composition.

Abstract: A sterile multi-dose ophthalmic consumer product, and especially a multi-dose low-concentration atropine eye drop container is disclosed having desirable atropine stability, low loss of viscosity, and low levels of total impurities leached from the container even after extended storage in the container.

Abstract: Disclosed are solid orodispersible pharmaceutical compositions in film form for oral administration of lorazepam, characterised by high stability throughout the shelf life of the product. The compositions disclosed are suitable for administration even to unconscious or dysphagic patients.

Abstract: The present invention relates to a multi-layer oral thin film comprising a matrix layer, which contains at least one polymer and at least one pharmaceutically active agent, and at least one backing layer, wherein the at least one backing layer comprises at least one polyethylene glycol, to a method for production of the oral thin film, and to the use of such an oral thin film as a medicament.

Abstract: The present invention relates to a method for producing a water-erodible, water-soluble or water-dispersible active-ingredient-administering form, in which, firstly, a film suitable as an oral film-administering form is produced which contains the active ingredient and in which a surface of the film is activated in a subsequent step in order to generate a tacky surface, followed by rolling up the activated film to form a rolled-up laminate. The present invention also relates to rolled-up laminates produced according to this method. Corresponding laminates are very stable, such that they can be dispensed and cut, and are suitable on account of their area density, which is very high by comparison with conventional OTF products, for administering active ingredients which have to be given in larger amounts.

Abstract: The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

Abstract: The invention relates to an aqueous suspension formulation for aerosol formation, said suspension formulation comprising lipid or lipidoid nanoparticles which are suspended in an aqueous vehicle solution, wherein the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a nucleic acid and (b) an ionizable lipid or an ionizable lipidoid; and wherein the aqueous vehicle solution comprises a triblock copolymer which contains one poly(propylene oxide) block and two poly(ethylene oxide) blocks. Moreover, the invention relates to an aerosol obtained from the formulation for aerosol formation.

Abstract: The present invention provides a hydrogel comprising hydroxyethyl cellulose (HEC) and bacteriophages.

Abstract: An oleogel composition comprises an ethylcellulose polymer, a first, non-volatile oil which is an active ingredient and a second oil selected from the group consisting of triglyceride oils and mineral oils.

Abstract: A composition configured for oral consumption and formulated to improve the delivery of supplemental creatine is provided. The composition comprises supplemental creatine and a liposomal blend configured to encapsulate the supplemental creatine. Encapsulating the supplemental creatine with the liposomal blend improves the bioavailability of the supplemental creatine by protecting the supplemental creatine from degradation caused by the user's digestive system. The liposomal blend may further bind to the user's small intestine permitting the supplemental creatine to pass directly into the user's bloodstream, where it is accessible to the user's muscles.

Abstract: A lipid nanoparticle (LNP) composition is provided. The composition includes a messenger RNA (mRNA) molecule; a lipid carrier system; and a toll-like receptor (TLR) antagonist.

Abstract: A shelf stable highly water soluble anhydrous powder composition of complexed macrocyclic lactones, formed by dissolving a macrocyclic lactone, a cyclodextrin, and a polysorbate compound in an organic solvent in specific ratios as outlined herein. The resultant organic solution is dried under oxygen and moisture free conditions to form an anhydrous powder composition.

Abstract: Among others, the present invention provides beta-hydroxybutyrate (BHB) salt granules, comprising BHB salts and fillers. The present invention also provides methods for producing BHB salt granules, wherein the BHB salt granules are prepared by granulation process. The production methods may include (a) wet granulation; (b) extrusion; (c) spheronization; and (d) drying.

Abstract: A lacosamide pharmaceutical composition as well as a preparation method and application thereof are provided. According to the lacosamide pharmaceutical composition, lacosamide or a pharmaceutically acceptable salt thereof can be dissolved out at the same time, wherein the dissolution rate of the lacosamide pharmaceutical composition is not more than 40% within 1 hour, the dissolution rate of the lacosamide pharmaceutical composition is 20-70% within 6 hours, and the dissolution rate of the lacosamide pharmaceutical composition is not less than 65% within 24 hours. The lacosamide pharmaceutical composition has good slow release performance, the tablet size can be rapidly expanded in the in-vitro dissolution process, the expanded lacosamide pharmaceutical composition has good rigidity and elasticity and has a remarkable retention effect in the stomach, and the cumulative release rate within 24 hours can reach 80% or above.

Abstract: Disclosed herein are polymeric implants and controlled release drug delivery systems to provide high drug loading and long-acting drug release. Provided herein are methods for making the same. Methods of administering pharmacologically active agents via the disclosed polymeric implants and controlled release drug delivery systems are also provided.

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

Abstract: The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Abstract: The present invention provides novel compositions, methods of treatment and methods of manufacture of large scale, commercially viable ibuprofen and acetaminophen tablets. The unique characteristics and synergistic effects resulting from the disclosed compositions, methods of treatment and methods of manufacture demonstrate a product with optimal analgesia, anti-pyresis, safety profiles and large-scale manufacturability. The inventions described herein surprisingly show the unique composition and method of manufacturing for a large-scale commercial batch of a novel ibuprofen and acetaminophen tablet.

Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.

Abstract: This invention, in some embodiments thereof, provides a core-shell nanoparticle including a lipid-PSMA conjugate, encapsulating a liquid oil-based core. The invention further provides aqueous compositions including the core-shell nanoparticles, and methods for using same, such as for the treatment of proliferative diseases associated with PSMA upregulated expression.

Abstract: The present invention provides novel nanostructures comprising solution of PPSU20. Methods of preparing the novel PPSU nanostructures, and applications of such nanostructures are also provided.

Abstract: Method for loading various molecules into plant-derived nanovesicles, comprising the following steps: a. suspending the isolated nanovesicles in a phosphate buffered saline; b. analyzing the suspended nanovesicles with a technique called “Nanoparticle Tracking Analysis” using a “Nanosight” for the evaluation of concentration and size distribution; c. re-suspending the nanovesicles in phosphate buffered saline; d. transferring the nanovesicles to sterile means; e. adding the fluorescent chemical to be loaded; f. treating the nanovesicles in the sterile means to facilitate the entry of the molecule to be loaded through their cell membrane; g. transferring the nanovesicles loaded with the desired molecule into ultra¬centrifuge tubes; h. re-suspending the pellet containing the nanovesicles in phosphate buffered saline and storing the supernatant obtained from the ultracentrifugation as a control for subsequent analysis; i. re-suspending the nanovesicles in phosphate buffered saline and proceed with testing.

Abstract: A composition including nanoparticle(s) having an iron oxide mineral core surrounded by a coating and a cryo-protectant. The core includes a first center activity and/or the coating includes a second center of activity, each of which are either: (A) a radio sensitizer/amplifier of radiation, an acoustic sensitizer/amplifier of acoustic radiation, a sonosensitizer/amplificatory of acoustic wave, a particle radiation sensitizer/amplifier of particle radiation; or (B) an attenuator of radiation, of light radiation, of acoustic radiation or wave, of particle radiation. Also a method of using the composition for increasing production of free radicals or amplifying radiation during a sonodynamic, photodynamic or radiation therapy or exposure of a body part to a radiation in the treatment of diseases.

Abstract: According to some embodiments, a method of providing treatment of a host comprises binding a carrier to cell structures of cells of the host to reduce a likelihood of an agent binding to said cell structures to at least partially inhibits the agent from binding to said cell structures, wherein the carrier comprises a core and a surface functionalized on the core, wherein the functionalized surface bind to target areas of cell structures of the host's cells, and wherein the carrier is to be used as targeted treatment for one or more disease, infections or allergic reactions caused by a disease-causing agent or source.

Abstract: A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

Abstract: The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; or (b) (i) vitamin C and/or selenium and (iii) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; or (c) a combination of (i), (ii) and (iii); wherein (a), (b) or (c) optionally further comprises vitamin E, in the manufacture of a product for therapeutically improving synaptic connectivity and/or therapeutically supporting memory and/or cognitive function in a human subject in need thereof.

Abstract: A dietary supplement includes a xanthophyll carotenoid including lutein, zeaxanthin, and meso-zeaxanthin. The dietary supplement may include, for example, greater than or equal to about 0.27 weight percent to less than or equal to about 0.47 weight percent of lutein, greater than or equal to about 0.066 weight percent to less than or equal to about 0.84 weight percent of zeaxanthin, and greater than or equal to about 0.27 weight percent to less than or equal to about 0.47 weight percent of meso-zeaxanthin.

Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodege

Abstract: This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Abstract: Described herein are compositions and methods for treating ovarian cancer. A method of treating ovarian cancer may include administering endoxifen in combination with a phosphoinositide 3-kinase inhibitor, such as alpelisib.

Abstract: In general, the invention relates to pharmaceutical compositions comprising (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI) and methods of treating Sleep Apnea comprising administering (R)-oxybutynin and a norepinephrine reuptake inhibitor (NRI). In some embodiments, the NRI is atomoxetine.

Abstract: An improved disinfectant composition in powder form for the post-milking teat disinfection of dairy animals is described. The composition has been proved to be well tolerable from the dermatological point of view, has a very appreciable persistence on skin, as well as a long-term storage stability.

Abstract: The present invention discloses a method for treating or preventing hereditary retinal dystrophy, the method comprising: administering a composition comprising a RIP1 inhibitor or a MLKL inhibitor to a subject in need thereof. The RIP1 inhibitor is, for example, RIPA-56, and the MLKL inhibitor is, for example, GW806742X.

Abstract: The present disclosure provides, amongst other things, pharmaceutical compositions, kits and methods for treatment of anal fissures using a medicated topical wipe comprising Nifedipine and Lidocaine.

Abstract: The present invention relates to a CXCL8 inhibitor and a pharmaceutical composition thereof, for use in the prevention or treatment of seizures.

Abstract: The present invention provides novel methods of initiating and escalating sotalol hydrochloride in patients in need thereof.

Abstract: Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.